Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy

Descripción del Articulo

Background: For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased pathologic complete response (pCR) rates, and improved survival. We evaluated the added prognostic value of re...

Descripción completa

Detalles Bibliográficos
Autores: Luen, SJ, Salgado, R, Dieci, MV, Vingiani, A, Curigliano, G, Gould, RE, Castaneda, C, D'Alfonso, T, Sanchez, J, Cheng, E, Andreopoulou, E, Castillo, M, Adams, S, Demaria, S, Symmans, WF, Michiels, S, Lo,i S
Formato: artículo
Fecha de Publicación:2019
Institución:Instituto Nacional de Enfermedades Neoplásicas
Repositorio:INEN-Institucional
Lenguaje:inglés
OAI Identifier:oai:repositorio.inen.sld.pe:inen/116
Enlace del recurso:https://repositorio.inen.sld.pe/handle/inen/116
Nivel de acceso:acceso abierto
Materia:RCB
TILs
TNBC
neoadjuvant
prognosis
https://purl.org/pe-repo/ocde/ford#3.02.21
id INEN_4baeb0b029777ad4e17f216288e16b5a
oai_identifier_str oai:repositorio.inen.sld.pe:inen/116
network_acronym_str INEN
network_name_str INEN-Institucional
repository_id_str .
spelling Luen, SJSalgado, RDieci, MVVingiani, ACurigliano, GGould, RECastaneda, CD'Alfonso, TSanchez, JCheng, EAndreopoulou, ECastillo, MAdams, SDemaria, SSymmans, WFMichiels, SLo,i S2024-07-01T16:28:49Z2024-07-01T16:28:49Z2019Background: For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased pathologic complete response (pCR) rates, and improved survival. We evaluated the added prognostic value of residual disease (RD) TILs to residual cancer burden (RCB) in predicting survival post-NAC. Patients and methods: We combined four TNBC NAC patient cohorts who did not achieve pCR. RD TILs were investigated for associations with recurrence-free survival (RFS), and overall survival (OS) using Cox models with stromal TILs as a continuous variable (per 10% increment). The likelihood ratio test was used to evaluate added prognostic value of RD TILs. Results: A total of 375 RD TNBC samples were evaluable for TILs and RCB. The median age was 50 years, with 62% receiving anthracycline/taxane chemotherapy. The RCB class after NAC was 11%, 50%, and 39% for I, II, and III, respectively. The median RD TIL level was 20% (IQR 10-40). There was a positive correlation between RD TIL levels and CD8+ T-cell density (ρ = 0.41). TIL levels were significantly lower with increasing post-NAC tumor (P = 0.005), nodal stage (P = 0.032), but did not differ by RCB class (P = 0.84). Higher RD TILs were significantly associated with improved RFS (HR: 0.86; 95% CI 0.79-0.92; P < 0.001), and improved OS (HR: 0.87; 95% CI 0.80-0.94; P < 0.001), and remained significant predictors in multivariate analysis (RFS P = 0.032; OS P = 0.038 for OS). RD TILs added significant prognostic value to multivariate models including RCB class (P < 0.001 for RFS; P = 0.021 for OS). The positive prognostic effect of RD TILs significantly differed by RCB class for RFS (PInt=0.003) and OS (PInt=0.008) with a greater magnitude of positive effect observed for RCB class II than class III. Conclusions: TIL levels in TNBC RD are significantly associated with improved RFS and OS and add further prognostic information to RCB class, particularly in RCB class II.application/pdf10.1093/annonc/mdy547https://repositorio.inen.sld.pe/handle/inen/116engAnn OncolUKElsevier Ltd.info:eu-repo/semantics/openAccessdc.rights.uri: https//creativecomons.org/licenses/by/4.0/RCBTILsTNBCneoadjuvantprognosishttps://purl.org/pe-repo/ocde/ford#3.02.21Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapyinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:INEN-Institucionalinstname:Instituto Nacional de Enfermedades Neoplásicasinstacron:INENPublicationORIGINALLuen 2019.pdfapplication/pdf399195https://repositorio.inen.sld.pe/bitstreams/6a922ee9-df48-441e-90cc-3092baed1146/download5ce8ca6e5db978a19c1b3e8e3ee1b974MD51TEXTLuen 2019.pdf.txtLuen 2019.pdf.txtExtracted texttext/plain33097https://repositorio.inen.sld.pe/bitstreams/b5379036-c7da-4aa6-829a-7f5f5f9403a6/downloadd5ff1fb9d6d0e1588ced8d4eaa0a29a2MD52THUMBNAILLuen 2019.pdf.jpgLuen 2019.pdf.jpgGenerated Thumbnailimage/jpeg4914https://repositorio.inen.sld.pe/bitstreams/24259e29-fdab-455e-a637-656114df9c68/downloadd8faf3c97a068f17a9ddaeb6e0455f15MD53inen/116oai:repositorio.inen.sld.pe:inen/1162024-10-23 18:10:05.355dc.rights.uri: https//creativecomons.org/licenses/by/4.0/info:eu-repo/semantics/openAccesshttps://repositorio.inen.sld.peRepositorio INENrepositorioinendspace@gmail.com
dc.title.none.fl_str_mv Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
title Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
spellingShingle Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
Luen, SJ
RCB
TILs
TNBC
neoadjuvant
prognosis
https://purl.org/pe-repo/ocde/ford#3.02.21
title_short Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
title_full Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
title_fullStr Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
title_full_unstemmed Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
title_sort Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
author Luen, SJ
author_facet Luen, SJ
Salgado, R
Dieci, MV
Vingiani, A
Curigliano, G
Gould, RE
Castaneda, C
D'Alfonso, T
Sanchez, J
Cheng, E
Andreopoulou, E
Castillo, M
Adams, S
Demaria, S
Symmans, WF
Michiels, S
Lo,i S
author_role author
author2 Salgado, R
Dieci, MV
Vingiani, A
Curigliano, G
Gould, RE
Castaneda, C
D'Alfonso, T
Sanchez, J
Cheng, E
Andreopoulou, E
Castillo, M
Adams, S
Demaria, S
Symmans, WF
Michiels, S
Lo,i S
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Luen, SJ
Salgado, R
Dieci, MV
Vingiani, A
Curigliano, G
Gould, RE
Castaneda, C
D'Alfonso, T
Sanchez, J
Cheng, E
Andreopoulou, E
Castillo, M
Adams, S
Demaria, S
Symmans, WF
Michiels, S
Lo,i S
dc.subject.none.fl_str_mv RCB
TILs
TNBC
neoadjuvant
prognosis
topic RCB
TILs
TNBC
neoadjuvant
prognosis
https://purl.org/pe-repo/ocde/ford#3.02.21
dc.subject.ocde.none.fl_str_mv https://purl.org/pe-repo/ocde/ford#3.02.21
description Background: For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased pathologic complete response (pCR) rates, and improved survival. We evaluated the added prognostic value of residual disease (RD) TILs to residual cancer burden (RCB) in predicting survival post-NAC. Patients and methods: We combined four TNBC NAC patient cohorts who did not achieve pCR. RD TILs were investigated for associations with recurrence-free survival (RFS), and overall survival (OS) using Cox models with stromal TILs as a continuous variable (per 10% increment). The likelihood ratio test was used to evaluate added prognostic value of RD TILs. Results: A total of 375 RD TNBC samples were evaluable for TILs and RCB. The median age was 50 years, with 62% receiving anthracycline/taxane chemotherapy. The RCB class after NAC was 11%, 50%, and 39% for I, II, and III, respectively. The median RD TIL level was 20% (IQR 10-40). There was a positive correlation between RD TIL levels and CD8+ T-cell density (ρ = 0.41). TIL levels were significantly lower with increasing post-NAC tumor (P = 0.005), nodal stage (P = 0.032), but did not differ by RCB class (P = 0.84). Higher RD TILs were significantly associated with improved RFS (HR: 0.86; 95% CI 0.79-0.92; P < 0.001), and improved OS (HR: 0.87; 95% CI 0.80-0.94; P < 0.001), and remained significant predictors in multivariate analysis (RFS P = 0.032; OS P = 0.038 for OS). RD TILs added significant prognostic value to multivariate models including RCB class (P < 0.001 for RFS; P = 0.021 for OS). The positive prognostic effect of RD TILs significantly differed by RCB class for RFS (PInt=0.003) and OS (PInt=0.008) with a greater magnitude of positive effect observed for RCB class II than class III. Conclusions: TIL levels in TNBC RD are significantly associated with improved RFS and OS and add further prognostic information to RCB class, particularly in RCB class II.
publishDate 2019
dc.date.accessioned.none.fl_str_mv 2024-07-01T16:28:49Z
dc.date.available.none.fl_str_mv 2024-07-01T16:28:49Z
dc.date.issued.fl_str_mv 2019
dc.type.none.fl_str_mv info:eu-repo/semantics/article
dc.type.version.none.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.doi.none.fl_str_mv 10.1093/annonc/mdy547
dc.identifier.uri.none.fl_str_mv https://repositorio.inen.sld.pe/handle/inen/116
identifier_str_mv 10.1093/annonc/mdy547
url https://repositorio.inen.sld.pe/handle/inen/116
dc.language.iso.none.fl_str_mv eng
language eng
dc.relation.ispartof.none.fl_str_mv Elsevier Ltd.
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
dc.rights.uri.none.fl_str_mv dc.rights.uri: https//creativecomons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv dc.rights.uri: https//creativecomons.org/licenses/by/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ann Oncol
dc.publisher.country.none.fl_str_mv UK
publisher.none.fl_str_mv Ann Oncol
dc.source.none.fl_str_mv reponame:INEN-Institucional
instname:Instituto Nacional de Enfermedades Neoplásicas
instacron:INEN
instname_str Instituto Nacional de Enfermedades Neoplásicas
instacron_str INEN
institution INEN
reponame_str INEN-Institucional
collection INEN-Institucional
bitstream.url.fl_str_mv https://repositorio.inen.sld.pe/bitstreams/6a922ee9-df48-441e-90cc-3092baed1146/download
https://repositorio.inen.sld.pe/bitstreams/b5379036-c7da-4aa6-829a-7f5f5f9403a6/download
https://repositorio.inen.sld.pe/bitstreams/24259e29-fdab-455e-a637-656114df9c68/download
bitstream.checksum.fl_str_mv 5ce8ca6e5db978a19c1b3e8e3ee1b974
d5ff1fb9d6d0e1588ced8d4eaa0a29a2
d8faf3c97a068f17a9ddaeb6e0455f15
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositorio INEN
repository.mail.fl_str_mv repositorioinendspace@gmail.com
_version_ 1841803064183357440
score 12.87381
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).